Efficacy of second-line chemotherapy or immune checkpoint inhibitors for patients with a prolonged objective response (≥ 6 months) after first-line therapy for recurrent or metastatic head and neck squamous cell carcinoma: a retrospective study.
Fiche publication
Date publication
juillet 2023
Journal
BMC cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOREL Christian
Tous les auteurs :
Vienne A, Collet L, Chevalier T, Borel C, Tardy M, Huguet F, Richard S, Salas S, Saada-Bouzid E, Fayette J, Daste A
Lien Pubmed
Résumé
Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) have a poor prognosis and limited therapeutic options. Immune checkpoint inhibitors (ICIs) are effective in patients with tumor progression < 6 months following first-line, platinum-based chemotherapy (PBC), but data are missing for patients with progression ≥ 6 months after the last platinum dose.
Mots clés
Diseases free interval, Head and neck, Immune checkpoint inhibitors, Platinum chemotherapy
Référence
BMC Cancer. 2023 07 14;23(1):663